fda compounding glp-1 Managing Compounded Medications: A Pharmacist's Guide for Employers – Sequoia Compounded GLP-1 crackdown? 🚨 FDA

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

A small note on air bubble anxiety: subcutaneous air bubbles are not dangerous

If you are navigating polycystic ovary syndrome (PCOS), hormonal acne, or metabolic health challenges, you may find yourself wondering if it is safe to combine specific treatments

In a March 3, 2026 press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies specifically for making claims that implied sameness with FDA-approved products - a category-wide compliance signal every buyer should understand